Clinical efficacy of enalapril maleate folic acid in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention
Xifu Wang,Haiyan Zi,Ping Jia,Xu Wang,Xuejun Ren
DOI: https://doi.org/10.3760/cma.j.issn.1673-4777.2016.07.004
2016-01-01
Abstract:Objective To observe the clinical efficacy of enalapril maleate folic acid in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention (PCI).Methods Totally 240 patients with ST-segment elevated myocardial infarction who underwent emergency PCI from March 2012 to December 2014 were randomly divided into enalaprilat group and enalapril folic acid group (120 cases in each group).Enalaprilat (5-20mg,1time/d) and enalapril folic acid (5-20mg,1time/d) was orally given in enalaprilat group and enalapril folic acid group,respectively.The left ventricular diastolic diameter (LVEDD),left ventricular ejection fraction (LVEF),the levels of plasma homocysteine (Hcy),high sensitivity C-reactive protein (hs-CRP),fibrinogen (FIB),brain natriuretic peptide (BNP) and angiotensin Ⅱ (Ang Ⅱ) on the admission day and 12 weeks after treatment were compared between groups.Results On the admission day,the LVEDD and LVEF were not significantly different between groups (P ＞ 0.05);12 weeks after treatment,the LVEDD was significantly reduced and the LVEF was significantly increased in both groups [enalaprilat group:(48 ± 5)mm vs (56 ± 5)mm,(59 ±9)％ vs (45 ±8)％;and enalapril folic acid group:(47 ±6)mm vs (57 ±5)mm,(61 ± 10)％ vs (49 ±8)％](P ＜ 0.05),while no significant differences were found between groups (P ＞ 0.05).The levels of plasma Hcy,hs-CRP,fibrinogen,brain natriuretic peptide and (Ang Ⅱ) on the admission day were not significantly different between groups (P ＞ 0.05);12 weeks after treatment,the Hcy level was not significantly changed in enalaprilat group [(20 ± 4)μmol/L vs (20 ± 4)μmol/L] (P ＞ 0.05) and was significantly reduced in the enalapril folic acid group [(14 ±4)μmol/L vs (21 ±4)μmol/L],(P ＜0.05),with significant difference between groups (P ＜0.05);12 weeks after treatment,the levels of hs-CRP,FIB,BNP and AngⅡ were significantly reduced [enalaprilat group:(6.5±0.4)mg/L vs (9.8±0.6)mg/L,(5.94±0.41)g/Lvs (8.86±0.39)g/L,(73±11)ng/L vs (126 ± 15)ng/L,(43 ± 10)ng/L vs (117 ±20)ng/L;enalapril folic acid group:(4.9 ±0.4)mg/L vs (9.4 ±0.6)mg/L,(4.43 ±0.29)g/Lvs (9.01 ±0.66)g/L,(64 ±11)ng/L vs (132±21)ng/L,(32 ±8)ng/L vs (109 ±21)ng/L] (P ＜0.01),with significant differences for Hcy,AngⅡ and hs-CRP between groups (P ＜0.05),but with no significant difference for BNP between groups (P ＞ 0.05).Conclusion Enalapril maleate folic acid can effectively reduce the levels of plasma Hcy,hs-CRP,FIB and Ang Ⅱ in patients with acute myocardial infarction,and plays a positive role in treating acute myocardial infarction in recovery period.